58results about How to "Efficacy of treatment" patented technology

The present invention identifies two circulating proteins that have been newly identified as being differentially expressed in atherosclerosis. Circulating levels of these two proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

Compositions and methods for treatment of conditions related to the overexpression of EZH2, such as late stage prostate cancer, using a DNA methylation inhibitor and/or a histone deacetylase inhibitor, optionally in combination with an EZH2 antagonist and/or an antineoplastic agent, to specifically target diseases associated with EZH2 over-expression. Further provided are reagents and kits for treatment of EZH2 overexpression.

The present invention identifies circulating proteins that are differentially expressed in atherosclerosis. Circulating levels of these proteins, particularly as a panel of proteins, can discriminate patients with acute myocardial infarction from those with stable exertional angina and from those with no history of atherosclerotic cardiovascular disease. Such levels can also predict cardiovascular events, determine the effectiveness of therapy, stage disease, and the like. For example, these markers are useful as surrogate biomarkers of clinical events needed for development of vascular specific pharmaceutical agents.

The invention relates to ophthalmology and is used for treating keratoconus. The inventive method comprises forming one or more radiation areas of different shape, comprising concentric circles, arcs, parallel lines, cells, grids, spirals or other geometrical figures. In the other variant, the method comprises polarizing UV radiation and adjusting the depth of the UV radiation action by directing the UV radiation polarization plane at an angle of 1-180° to the plane of light polarization by the cornea, thereby using the effect of light polarization by the cornea. The device for treating keratoconus comprises, positioned on the optical axis common with an UV radiation source optical focusing elements and a diaphragm. The diaphragm is situated on the optical axis common with the UV radiation source and is made in the form of a mask with alternating transparent and shaded elements in the form of concentric circles, arcs, parallel lines, cells, grids, spirals or other geometrical figures. In the other variant, the device comprises, situated on the optical axis common with the UV radiation source, the optical focusing elements, the diaphragm and a polarisor.

The invention relates to the use of tetramethylpyrazine (TMP) for the treatment of patients at risk for the development of, or diagnosed as having, CNS disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), glaucoma, and Huntington's Disease (HD), as well as traumatic brain injury (TBI). The present invention also relates to the use of retinal imaging to diagnose and monitor efficacy of treatments for such CNS disorders.

The invention relates to a prosthesis that is compressible and expandable in a radial direction, intended to be implanted in the digestive tract of a patient. According to the invention, such a prosthesis comprises: a downstream conical collar having end diameter D3, a main tabular body having diameter D2, an upstream conical collar having end diameter D1, said upstream collar not being covered by any material and having an end diameter D1 greater than the diameter D2 of said main body and greater than the end diameter D3 of said downstream collar, and said downstream collar being fully or partially covered by at least one polymer material.

The present invention provides a composition for dermal application

which comprises, as an active ingredient, an oxidized coenzyme Q represented by the formula (1):

in which n represents an integer of 1 to 12, and/or a reduced coenzyme Q represented by the formula (2):

in which n represents an integer of 1 to 12, the total content of the oxidized coenzyme Q and reduced coenzyme Q being 0.01 to 99% by weight relative to the whole amount of the composition. The present invention also provides a therapeutic composition for skin diseases, a cosmetic composition, a skin health care composition and a bath salt composition, each comprising the above composition for dermal application. The present invention is further provides a method for the treatment of skin diseases which comprises applying, to a patient suffering from a skin disease, the above-mentioned therapeutic composition for skin diseases, or a method for the treatment of skin diseases which comprises applying, to a patient suffering from a skin disease, the above therapeutic agent for skin diseases other than the oxidized coenzyme Q represented by the formula (1) and other than the reduced coenzyme Q represented by the formula (2) in parallel with a therapeutic composition for skin diseases.

A system and method for targeting relevant research activity for clinical application in response to diagnostic markers analyses is described. Diagnostic analysis is performed to detect the level of each of at least three diagnostic markers. The levels of the tested markers are used to identify relevant publications from among a large database of articles. The most relevant literature, such as, one which reports research and studies that have been conducted to identify, moderate, and define the mechanisms unique to individual and combinations of diagnostic markers for various disease states, is then provided to the patient and/or the patient's physician, optionally with a summarization of the treatment recommendations from the provided literature. The customized information delivery provides a range of published peer-reviewed therapeutic options and/or published research studies.

The invention pertains to methods that include administering to a subject a transoral dosage form comprising a pharmaceutical carrier and sufentanil, and maintaining a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test. Related dosage forms are also disclosed. Also disclosed are transoral dosage forms and related methods, wherein a transoral dosage form may comprise: (1) about 5 to about 1000 micrograms of sufentanil; (2) about 50 micrograms to about 100 milligrams of naloxone; and (3) acidifying material in an amount sufficient to provide a mean pH ranging from about 3.5 to about 5.5 during a dosing period after administration of the transoral dosage form as determined using an in vitro donor media test; wherein the dosing period begins no earlier than about 1 minute after administration of the transoral dosage form, and ends no later than about 120 minutes after administration of the transoral dosage form.

A Ramipril formulation which is suitably stabilised to control the degradation to the active metabolite ramiprilat.

The present invention relates to methods of diagnosing a liver disorder in a patient, as well as methods of monitoring the progression of a liver disorder and/or methods of monitoring a treatment protocol of a therapeutic agent or regimen. The invention also relates to assay kits used in connection with the diagnostic methods described herein.

The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene expression level of at least 7 genes selected from the group consisting of CCR2, CD3D, CD3E, CD3G, CD8A, CXCL10, CXCL11, GZMA, GZMB, GZMK, GZMM, IL15, IRF1, PRF1, STAT1, CD69, ICOS, CXCR3, STAT4, CCL2, and TBX21, ii) comparing every expression level determined at step i) with their predetermined reference value and iii) providing a good prognosis when all expression levels determined at step i) are higher than their predetermined reference values, or providing a bad prognosis when all expression levels determined at step i) are lower than their predetermined reference values or providing an intermediate prognosis when at least one expression level determined value is higher than its predetermined value. The method is also particularly suitable for predicting the responsiveness of the patient to a treatment.

Described herein are methods for quantifying lAIP levels in a sample (e.g., from a subject) using lAIP ligand-based assays. Also disclosed are methods for measuring lAIP-IAIP ligand complexes, and methods of evaluating, monitoring, and treating subjects using the aforementioned lAIP quantification methods.

The present invention provides methods for identifying IBD patients with dysplasia or cancer. In particular embodiments, the methods of the invention may comprise determining the presence or level of at least one or a panel of miRNAs in a sample obtained from an IBD patient to establish a miRNA expression profile, and comparing the miRNA expression profile with one or more pre-established model miRNA expression profiles. The present invention further provides methods for monitoring the efficacy of treatment of IBD patients with dysplasia or cancer.

Activated lymphocytes are administered to a cancer patient at least five or more times within eight months after performing surgical and chemotherapeutic treatment or radiotherapy for treating cancer particularly liver cancer, so that recurrence of the cancer can be prevented over a long period of five or more years. The activated lymphocytes to be administered while performing treatment of cancer may be autologously derived from a cancer patient or collected from the other cancer patient at need. The activated lymphocytes can be cultivated for proliferating or activating lymphocyte cells collected in the presence of solid-phase anti-CD3 antigen and interleukin 2.

A method for monitoring a therapeutic treatment regime in an individual having a disease, comprises: providing at a first location a solid substrate capable of immobilising a biomarker characteristic of the disease and a therapeutic compound in the biological sample, contacting the biological sample with the solid substrate to immobilise the biomarker and the therapeutic compound; transferring the solid substrate with the immobilised biomarker and therapeutic compound to a second location; performing an extraction step on the solid substrate to extract the biomarker and the therapeutic compound; performing a first detection assay to detect and/or quantify the biomarker, performing a second detection assay to quantify the therapeutic compound; and correlating the detection and/or quantity of the biomarker with the disease state of the individual, and comparing the quantity of the therapeutic compound with a target level for treatment of the disease, thereby to assess the efficacy of the treatment regime.